Kiranol

Dorzolamide Hydrochloride, the active ingredient in Kiranol, is a carbonic anhydrase inhibitor presented as an eye drops solution for ocular (topical) use. It, together with timolol maleate, reduces intra‑ocular pressure in patients with glaucoma or ocular hypertension. GNH USA supplies Kiranol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kiranol is used in the management of ocular conditions that involve elevated intra‑ocular pressure. - Primary open‑angle glaucoma: lowers intra‑ocular pressure to slow optic nerve damage. - Secondary open‑angle glaucoma: reduces pressure when caused by other ocular diseases. - Ocular hypertension: controls pressure in eyes without established glaucomatous damage.

Kiranol may cause a range of ocular and systemic reactions.

Common Side Effects: - Burning or stinging sensation in the eye - Transient blurred vision - Dry eye or foreign‑body feeling - Taste alteration after drainage - Redness of the conjunctiva - Mild headache

Serious or Rare Side Effects: - Severe allergic reaction (angio‑edema, anaphylaxis) - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Corneal edema or ulceration - Systemic beta‑blocker effects (bradycardia, bronchospasm) - Acute angle‑closure glaucoma (paradoxical rise in pressure)

Before using Kiranol, consider the following precautions. - Cardiovascular assessment: monitor heart rate and blood pressure in patients with cardiac disease. - Respiratory status: avoid in patients with severe asthma or COPD due to beta‑blockade. - Sulfonamide allergy: discontinue if hypersensitivity to sulfonamide derivatives is known. - Pregnancy and lactation: use only if the potential benefit outweighs the risk, as safety data are limited. - Contact lens wearers: remove lenses before instillation and wait at least 15 minutes before reinserting. - Store at room temperature: keep the bottle tightly closed, protect from light and moisture.

Kiranol can interact with other systemic and ocular agents.

Major Interactions (Avoid): - Systemic non‑selective beta‑blockers (e.g., propranolol) – may cause additive bradycardia or hypotension. - Calcium channel blockers (e.g., verapamil) – can enhance intra‑ocular pressure‑lowering effect and systemic hypotension. - Monoamine oxidase inhibitors – may increase risk of severe hypotension.

Moderate Interactions (Monitor Closely):\n- Antihypertensive agents (e.g., ACE inhibitors) – monitor blood pressure for additive lowering. - Diuretics – watch for electrolyte disturbances that could affect ocular fluid dynamics. - NSAIDs used topically – may increase risk of corneal irritation.